Research paper
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
About this item
- Title
- HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
- Content partner
- Directory of Open Access Journals
- Collection
- Directory of Open Access Journals
- Description
Abstract Background HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively evaluate the prognostic/predictive significance of the above parameters in early, high-risk breast cancer patients treated with epirubicin-based, dose-dense sequential adjuvant chemotherapy. Methods In a series of 352 breast carcinoma tissues from patients that had been ...
- Format
- Research paper
- Date created
- 2012-01-01
- Creator
- Fountzilas George / Valavanis Christos / Kotoula Vassiliki / Eleftheraki Anastasia G / Kalogeras Konstantine T / Tzaida Olympia / Batistatou Anna / Kronenwett Ralf / Wirtz Ralph M / Bobos Mattheos / Timotheadou Eleni / Soupos Nikolaos / Pentheroudakis George / Gogas Helen / Vlachodimitropoulos Dimitrios / Polychronidou Genovefa / Aravantinos Gerasimos / Koutras Angelos / Christodoulou Christos / Pectasides Dimitrios / Arapantoni Petroula
- Contributing partner
- Journal of Translational Medicine
- URL
- http://www.translational-medicine.com/content/10/1/10
- Related subjects
- HER2 / TOP2A / gene amplification / CISH / mRNA expression / early breast cancer / randomized study / anthracyclines / taxanes / Medicine
What can I do with this item?
Check copyright status and what you can do with this item
Check informationReport this item
If you believe this item breaches our terms of use please report this item
Report this itemDigitalNZ brings together more than 30 million items from institutions so that they are easy to find and use. This information is the best information we could find on this item. This item was added on 03 November 2014, and updated 19 July 2018.
Learn more about how we work.
Share
What is the copyright status of this item?

Share, Modify, Use commercially
See below for specifics about how you may use this item.

More Information
Directory of Open Access Journals has this to say about the rights status of this item:
CC BY (All metadata for this Directory of Open Access Journals record is available under the Creative Commons Attribution-ShareAlike License (CC BY-SA).)
You can learn more about the rights status of this item at: http://www.biomedcentral.com/getpublished/copyright-and-license
What can I do with this item?
You must always check with Directory of Open Access Journals to confirm the specific terms of use, but this is our understanding:

Non-infringing use
NZ Copyright law does not prevent every use of a copyright work. You should consider what you can and cannot do with a copyright work.

Share it
This item is suitable for copying and sharing with others, without further permission.

Modify it
This item is suitable for modifying, remixing and building upon, without further permission.

Use it commercially
This item is suitable for commercial use, without further permission.
What can I do with this item?
Check copyright status and what you can do with this item
Check informationReport this item
If you believe this item breaches our terms of use please report this item
Report this itemDigitalNZ brings together more than 30 million items from institutions so that they are easy to find and use. This information is the best information we could find on this item. This item was added on 03 November 2014, and updated 19 July 2018.
Learn more about how we work.
Share
Related items
Loading...